Small molecule compounds targeting the p53 pathway: are we finally making progress?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The p53 tumor suppressor gene is the most frequently mutated gene in human cancers.
• Loss of p53 function is critical for cancer development, making its pathway a key therapeutic target.

Purpose of the Study:

• To review current literature on small-molecule drugs targeting wild-type and mutant p53.
• To discuss drug discovery methods and mechanisms of action for p53-targeting agents.
• To outline the developmental status of these drugs and identify future therapeutic avenues.

Main Methods:

• Literature review of small-molecule compounds targeting p53.
• Classification of drugs based on their mechanisms of action.
• Analysis of current clinical trial data for p53-targeting therapeutics.

Main Results:

• Significant progress has been made in discovering small molecules that target both wild-type and mutant p53.
• The first in-human clinical trials for several p53-targeting drugs have been initiated and completed.
• Various approaches are being explored to pharmacologically activate the p53 pathway.

Conclusions:

• Pharmacologic activation of the p53 pathway represents a promising, yet challenging, therapeutic strategy in cancer treatment.
• Small-molecule drugs targeting p53 are advancing through clinical development.
• Emerging insights into p53 tumor biology may reveal novel therapeutic targets.